SubHero Banner

Leqvio® (inclisiran) – New drug approval– New indication

On December 22, 2021, Novartis announced the FDA approval of Leqvio (inclisiran), as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia (HeFH) or clinical atherosclerotic cardiovascular disease (ASCVD), who require additional lowering of low-density lipoprotein cholesterol (LDL-C).

Download PDF